Dyadic appoints doug pace to its executive leadership team

Jupiter, fla., oct. 09, 2023 (globe newswire) -- dyadic international, inc. (“dyadic”, “we”, “us”, “our”, or the “company”) (nasdaq: dyai), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced the appointment of doug pace as executive vice president of business development. the expansion of dyadic's management team is in response to the increased interest in the company's microbial platforms, specifically the c1 technology for infectious disease and other recombinant vaccines and antibodies for human and animal pharmaceutical use, and the dapibus™ platform for non-pharmaceutical applications for large nutritional markets such as dairy proteins and enzymes as well as cell culture markets for recombinant serum albumin.
DYAI Ratings Summary
DYAI Quant Ranking